Apyx Medical UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
UBS MedTech team, thank you so much for joining, and massive thank you to Charlie Goodwin for agreeing to do this, from Apyx Medical, as CEO. Charlie, I think maybe what would be amazing is if you could give people a little bit of a background to yourself. I know you've been at the firm for a while now, but a little bit of a history of you and then just a brief Okay, perfect.
Thank you very much, Patrick. Thanks for having us, and thanks to UBS for inviting us to the conference. My name is Charlie Goodwin. I'm the CEO of Apyx Medical. I have been the CEO of Apyx Medical since December of 2017, and we transformed this company from a prior company, it was called Bovie Medical, which everybody's obviously heard about in the RF space. In January of 2019, we became Apyx Medical with a focus on surgical aesthetics. We had a product called Renuvion, a technology called Renuvion, that was used after liposuction and body contouring for skin tightening. We built a business around that, and then just last year, we launched AYON, which is a complete body contouring solution that has two forms of liposuction. It has dedicated fat transfer.
It's obviously got the Bovie generator, so you can do all surgical procedures, and it has Renuvion for skin tightening to be able to complete the entire body contouring procedure with AYON. We launched that about a year ago. Just later this year, we finished a power-assisted handpiece for the second form of liposuction, so now AYON is 100% complete, and we are in the process of now trying to register that throughout the world so we can sell it everywhere, because right now we're only commercialized it so far in the United States. My background is I have been in medical device now for 35 years, although Patrick, you got to admit, it doesn't look that long if you're looking at me. But I actually have been in medical devices for 35 years. Been all focused on the surgical side of things.
As I came here to Apyx, that was the first time in aesthetics, and it's probably not a surprise that we're focused on the surgical side of aesthetics, and we think that Apyx can be the largest surgical company in aesthetics. We think surgery is incredibly relevant in aesthetics because we believe it is the only thing that provides durable and transformational results. We also believe that because of the disruption of the marketplace for the GLP-1 drugs, that most of those patients are going to benefit from a surgical intervention to get their bodies contoured back after the weight loss that they've had because of these drugs. We think that we are positioned incredibly well to be able to grow for many years to come.
We're very proud that in this last earnings call that we just had on Thursday, that the trailing last four months, we have got the EBITDA positive. We've taken a small company and we've dramatically lowered the burn that is there, and we think that with AYON and Renuvion, we can grow for a long, long time.
I definitely want to hit on the GLP-1 side later. Pretty much everybody in the town I live is microdosing that, which is kind of entertaining. But maybe for those who are less familiar with Renuvion and helium plasma specifically as an approach, some of the background of the technology and the relative advantages versus other approaches might be helpful.
Okay. Renuvion is an amazing technology, and historically, it has been used to tighten the skin after a liposuction procedure. If you think about the removal of fat for liposuction, the last thing you want to have happen is to not have that finish or not have that tight look. If you just do lipo without Renuvion, you can look much better in your clothes, but you won't look that great on the beach, and everybody wants to look really good on the beach. Renuvion has done that. We've always believed in evidence-based medicine for Renuvion, and so I believe that Renuvion is the most researched technology of its type in aesthetics. We've got over 100 clinical papers that talk about the safety and efficacy of Renuvion. Renuvion is also a cold atmospheric plasma.
I won't go into the science behind that, but cold atmospheric plasma is being studied all throughout medicine, and there's two other studies that we have done. One just came out in September, but there's two other areas of Renuvion that are being used in aesthetics. The first is, we did a study that if you pre-treat an area with Renuvion before you do fat transfer, you get a 40% higher viability of the fat long term with that, and that has to do with the cold atmospheric plasma portion of Renuvion, and that becomes incredibly important, obviously, in something like a BBL, where you're going to take fat from other parts of the body and put it in the butt.
One of the fastest growing procedures that is out there is scarless mastopexy, which is into the breast, and it's incredibly relevant in the GLP-1 drugs because when women lose weight, one of the places that they lose weight first is in their breast, and quite honestly, it's one of the last places they'd want to lose weight. A lot of women don't want to have an implant, so you take fat from part of the body, you put it in the breast, and you help the aesthetics that way. So that is a study that we did that talks about another utility for Renuvion. The one that just came out in September is the one I am most excited about because we have always heard from longtime Renuvion customers that the quality of the skin gets better after they use Renuvion.
We actually did a study on the face where we treated part of the face underneath with Renuvion, and then we had a control area that wasn't treated with Renuvion, and it showed that Renuvion formed over 30% more elastin growth underneath the skin, which is huge because that is like Ponce de León and the Fountain of Youth. It is regenerative in nature to have your body produce more elastin. So not only did it have 30% more elastin, it also had over 30% less inflammation also. So that is a study that just came out in September. If you look at our total revenue, which I think this year is going to be about $54 million, about half of that is in the disposable Renuvion handpieces. So we do have a very nice recurring business of Renuvion.
There's over 90,000 Renuvion procedures that are done every year, so it's not a small number of procedures. It has been something that has grown this business from zero to where we are today. So we're very happy with what's happened with Renuvion, but we're incredibly excited about the future of Renuvion based on the last two clinical studies that I talked about.
Always nice to hear about the science, and you never bore me with it. I watched an hour-long video about liquid hydrogen, so I'm that kind of guy, so I get it. Maybe you could walk us through the AYON system and the appeal for the surgeons themselves and why they would pick that kind of a solution.
We obviously were the one technology company that had Renuvion, and we started to look as an organization where we could have the biggest impact on aesthetics. As I mentioned before, we're a big believer of surgical aesthetics for the durable and transformational results for it. When we started to look at the marketplace, there wasn't any meaningful innovation that had gone on in liposuction in almost 20 years. The other side of it is it was incredibly fragmented market with a lot of smaller players, and in our opinion, it was an area that was ripe for disruption.
What we did as a company is we went out and started to work with some of the top body contouring doctors in the world, and we basically gave them a blank slate and said, "Okay, from a technology point of view, what would you want to have improved? From a workflow perspective, what would you want to have improved? What features are not there today that you would love to be able to see in a body contouring system?" We had them design the entire system from scratch. We also took a look at pain points that they had from a reliability, a usability, all of those types of things, huge list, and gave it to our development team, and our development team did a phenomenal job and developed AYON. What is AYON? AYON is the ultimate body contouring system in the world today.
It has two forms of liposuction. It's got ultrasonic liposuction, and it's got power-assisted liposuction. It's got aspiration. It has infiltration. It has a closed loop for fat transfer, so you can take the fat out and put it back into the breast or the butt, as we talked about before. It has an electrosurgical generator, so there is not a surgical procedure that the doctor cannot do in aesthetics with AYON. It really is the only surgical system that an aesthetic doctor needs to do any form of body contouring or any surgery there. Every technology that is in AYON is better than the existing technologies today.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
